Evidence map›Paper›PMID 32472498›Full record

ReviewJournal of cardiovascular translational research2020

Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.

Rafey A Feroze, Jeff Leya, Todd Herron, Salim S Hayek

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Imaging Value ofMolecular imaging and biology · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rafey A FerozeDepartment of Medicine, University of Michigan, Ann Arbor, MI, USA.
Jeff LeyaDivision of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
Todd HerronDivision of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
Salim S HayekDivision of Cardiology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA. shayek@med.umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expansion of cancer therapeutics has paved the way for improved cancer-related outcomes. Cardiotoxicity from cancer therapy occurs in a small but significant subset of patients, is often poorly understood, and contributes to adverse outcomes at all stages of cancer treatment. Given the often-idiopathic occurrence of cardiotoxicity, novel strategies are needed for risk-stratification and early identification of cancer patients experiencing cardiotoxicity. Clinical and research tools extending from imaging to blood-based biomarkers and pluripotent stem cells are being explored as methods to study the cardiovascular impact of various cancer treatments. Here we provide an overview of tools currently available for evaluation of cardiotoxicity and highlight novel techniques in development aimed at understanding underlying pathophysiologic mechanisms.

Indexed as

Cancer SurvivorsAnimalsAntineoplastic AgentsBiomarkersCardiac Imaging TechniquesCardiotoxicityCardiovascular DiseasesHumansInduced Pluripotent Stem CellsMyocytes, CardiacNeoplasmsPrognosisRisk AssessmentRisk FactorsVentricular Function, LeftAntineoplastic AgentsBiomarkersBiomarkersCardiac CTCardiac MRICardio-oncologyCardiotoxicityNuclear imaging

Identifiers

PMID32472498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.